The MIR-NAT MAPT-AS1 does not regulate Tau expression in human neurons

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Tau protein, encoded by the MAPT gene, aggregates in neurodegenerative diseases like Alzheimer's.
• Understanding Tau regulation is crucial for developing effective Alzheimer's disease (AD) treatments.
• Natural antisense transcripts (NATs) are long non-coding RNAs (lncRNAs) that can modulate gene expression.

Purpose of the Study:

• To investigate the role of MAPT antisense 1 (MAPT-AS1) lncRNA in regulating MAPT gene expression.
• To determine if MAPT-AS1 is a potential therapeutic target for reducing Tau levels in tauopathies.

Main Methods:

• Expression of MAPT-AS1 was modulated in human neuroblastoma cell lines and induced pluripotent stem cell (iPSC)-derived neurons.
• MAPT mRNA and Tau protein levels were analyzed following MAPT-AS1 modulation.

Main Results:

• Modulating MAPT-AS1 expression did not alter MAPT mRNA or Tau protein levels.
• Contrary to previous reports, MAPT-AS1 did not demonstrate a regulatory role in Tau expression in vitro.

Conclusions:

• MAPT-AS1 does not appear to regulate Tau expression in human neurons.
• MAPT-AS1 is unlikely to be a therapeutic target for lowering Tau in Alzheimer's disease or other tauopathies.